A Better Path Forward.

Multi-Pronged Approach

  • Orally administered RSV Fusion inhibitor
  • High potency against RSV A and RSV B strains
  • Antiviral levels achieved in plasma
  • Lack of clinical resistance
  • Favorable Toxicity and Tolerability Profile
  • Highly potent activity against virus and symptoms in RSV challenge model
  • View publication of RSV Challenge Study Data
  • Partnered with LianBio (www.lianbio.com) for development and commercialization in mainland China, Hong Kong, Macau, and Singapore
N-Protein Inhibitors
  • Potential for monotherapy or combination therapy
  • Complementary mode of action to sisunatovir – targets different stage of viral life cycle
  • Demonstrated additive combination effect in vitro